Second-Generation Antihistamines: Why Fexofenadine (Xofedin 120) is the Preferred Daytime Choice

The Challenge of First-Generation Antihistamine Sedation

First-generation antihistamines readily cross the blood-brain barrier, occupying central H1 receptors and inducing profound drowsiness, impaired psychomotor performance, and reduced daytime work efficiency. In professional and student populations, this sedative burden can severely impact daily functioning.

Peripheral Selectivity of Xofedin 120

Xofedin 120 contains Fexofenadine Hydrochloride USP 120 mg, the active carboxylic acid metabolite of terfenadine. Due to its zwitterionic molecular structure, Fexofenadine demonstrates virtually zero penetration through the blood-brain barrier, offering genuine non-sedating relief.

Clinical Highlights:

• Rapid 1-Hour Onset: Clinically proven reduction in sneezing, ocular itching, and watery rhinorrhea within 60 minutes of oral administration.
• True 24-Hour Duration: Convenient once-daily dosing sustaining continuous H1 blockade throughout the working day and overnight.
• Clean Cardiac Profile: Devoid of cardiotoxic QT-prolongation effects associated with older second-generation compounds.

Xofedin 120 is indicated for seasonal allergic rhinitis and chronic idiopathic urticaria in adults and adolescents aged 12 years and older.